Tessera Therapeutics vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Tessera Therapeutics is developing Gene Writing technology to insert large therapeutic sequences directly into the genome without double-strand DNA breaks; raised $230M+ including a $100M Series B;
About
Tessera Therapeutics is a genomic medicine company founded in 2018 by Jacob Rubens, Brian Goodman, and colleagues at Flagship Pioneering (the life sciences venture creation firm behind Moderna) and headquartered in Cambridge, Massachusetts. The company is pioneering Gene Writing — a platform technology that uses mobile genetic elements (specifically RNA-guided integrases derived from retrotransposons) to write large DNA sequences directly into the human genome at targeted sites, without requiring double-strand DNA breaks. This approach is designed to overcome key limitations of first-generation gene editing technologies: CRISPR-Cas9 creates double-strand breaks that can introduce unintended mutations, and current gene editing tools are largely limited to small sequence corrections or knockouts rather than full gene insertions.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.